In this article (Clin Cancer Res 2014;20:5133–9), which was published in the October 1, 2014, issue of Clinical Cancer Research (1), clinical stage groups “T1,” “T2a–T2b,” and “Tx” in Table 1 were mislabeled—they should read as follows: “T1–T2a,” “T2b,” and “Unknown,” respectively. The corrected table is provided below. The results and conclusions put forth in this article remain unchanged. The authors regret this error.
Table 1.
Clinical characteristics of the study patients with localized prostate cancer
| Characteristics . | N (%) . |
|---|---|
| Total | 1,827 |
| Age at diagnosis, years | |
| Median (range) | 62 (31–87) |
| Clinical stage, n (%) | |
| T1–T2a | 1,504 (82.3) |
| T2b | 142 (7.8) |
| T2c–T4 | 168 (9.2) |
| Unknown | 13 (0.7) |
| PSA level at diagnosis, ng/mL | |
| <4 | 453 (24.8) |
| 4–10 | 1,147 (62.8) |
| 10–20 | 154 (8.4) |
| ≥20 | 70 (3.8) |
| Unknown | 3 (0.2) |
| Biopsy-proven GS | |
| ≤6 | 675 (36.9) |
| 7 | 921 (50.4) |
| ≥8 | 231 (12.6) |
| D'Amico risk group | |
| Low | 608 (33.3) |
| Intermediate | 861 (47.1) |
| High | 346 (18.9) |
| Not grouped | 12 (0.7) |
| Primary treatment | |
| Radical prostatectomy | 947 (51.8) |
| Radiotherapy | 390 (21.3) |
| Other treatmenta | 49 (2.7) |
| Surveillance or unknownb | 441 (24.1) |
| Characteristics . | N (%) . |
|---|---|
| Total | 1,827 |
| Age at diagnosis, years | |
| Median (range) | 62 (31–87) |
| Clinical stage, n (%) | |
| T1–T2a | 1,504 (82.3) |
| T2b | 142 (7.8) |
| T2c–T4 | 168 (9.2) |
| Unknown | 13 (0.7) |
| PSA level at diagnosis, ng/mL | |
| <4 | 453 (24.8) |
| 4–10 | 1,147 (62.8) |
| 10–20 | 154 (8.4) |
| ≥20 | 70 (3.8) |
| Unknown | 3 (0.2) |
| Biopsy-proven GS | |
| ≤6 | 675 (36.9) |
| 7 | 921 (50.4) |
| ≥8 | 231 (12.6) |
| D'Amico risk group | |
| Low | 608 (33.3) |
| Intermediate | 861 (47.1) |
| High | 346 (18.9) |
| Not grouped | 12 (0.7) |
| Primary treatment | |
| Radical prostatectomy | 947 (51.8) |
| Radiotherapy | 390 (21.3) |
| Other treatmenta | 49 (2.7) |
| Surveillance or unknownb | 441 (24.1) |
aCryoablation, high-intensity focused ultrasound, transurethral resection of prostate, or androgen deprivation therapy.
bPatients undergoing active surveillance/watchful waiting or whose initial treatment information was unavailable.
References
1.
He
Y
, Gu
J
, Strom
S
, Logothetis
CJ
, Kim
J
, Wu
X
. The prostate cancer susceptibility variant rs2735839 near KLK3 gene is associated with aggressive prostate cancer and can stratify Gleason score 7 patients
. Clin Cancer Res
2014
;20
:5133
–9
.©2015 American Association for Cancer Research.
2015
